Speaker Profile
Ph.D., MBA, President & CEO, Moleculera Labs, Inc
Biography
Craig Shimasaki has over 35 years of biotechnology industry experience and started his career at Genentech. His work spans all stages of research and development from bench-to-bedside that includes epitope mapping for an HIV vaccine, genetic breast cancer risk prediction biomarkers, a rapid influenza diagnostic, and therapeutics for infectious diseases, neuropsychiatric disorders, and noise-induced hearing loss. He co-founded several companies, led multiple products through the FDA approval process, and is a co-inventor on multiple patents. Dr. Shimasaki received his BS in biochemistry from the University of California at Davis, his PhD in molecular biology from the University of Tulsa, and his MBA from Northwestern University's Kellogg School of Business. He is an Adjunct Professor at the University of Oklahoma and teaches biotechnology entrepreneurship. His passion is to help translate scientific and medical discoveries into acutely needed products so that more patients can live healthier lives.
Talk
Precision Medicine Approach to Testing for Immune-Mediated Neuropsychiatric Disorders
Moleculera Labs detects brain-directed, immune-mediated autoantibodies in patients suffering from commonly known neurologic, psychiatric, and behavioral disorders. Patients suffering from schizophrenia, autism, PANSPANDAS, and others, benefit from a precision medicine approach as test-postive patients respond to immune modulators and anti-inflammatory therapies. Our 15,000 specimen biobank is used for the development of follow-on productstreatment targets.
Clinical Dx Showcase:
Moleculera Labs, Inc
Moleculera Labs performs a blood panel that identifies immune-mediated neuropsychiatric and mental disorders. This Autoimmune Brain Panel detects serum autoantibodies targeting specific brain markers, which guide physicians to highly effective anti-inflammatory and immune modulatory treatments that resolve the underlying cause rather than ineffectively treating symptoms.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
